Osi Osimertinib
Description: <b>Osimertinib</b> works by selectively inhibiting the activity of EGFR, which is a protein that plays a critical role in the growth and survival of cancer cells. By blocking the activity of EGFR, osimertinib prevents the growth and proliferation of cancer cells, leading to tumor shrinkage and improved survival.<br>
Osimertinib has been shown to be effective in patients with NSCLC who have specific EGFR mutations. In the AURA3 trial, osimertinib significantly improved progression-free survival (PFS) compared with platinum-based chemotherapy. In the FLAURA trial, osimertinib significantly improved PFS and overall survival (OS) compared with erlotinib or gefitinib.<br>